Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)

Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are prescribed to alleviate the pain and enhance mobility, but more-effective, well-tolerated alternatives are needed. Although there has been little recent innovation in this space, the pipeline for OA pain is active and diverse; several agents with novel mechanisms of action are in Phase 3 development (e.g., Grünenthal’s resiniferatoxin, Kolon’s TG-C). In this crowded and generic market, a deep understanding of patient characteristics, treatment patterns, and the competitive landscape is essential for the successful introduction of a novel analgesic.

Questions answered

• What is the potential clinical and commercial impact of agents in the OA pain pipeline?
• Where would emerging agents fit into the treatment algorithm for OA pain?
• What are the most pressing unmet needs in OA pain, and how well would pipeline agents fulfill them?

Content highlights

Geographies: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading pain specialists and rheumatologists, supported by survey data collected for this and other Clarivate research

Epidemiology: Number of osteoarthritic pain patients by country, including diagnosed and drug-treated osteoarthritic pain patients

Forecast: 10-year, annualized, drug-level sales and patient share of key OA pain therapies through 2034, segmented by brands / generics

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.